Skip to content
Business Times – Lifestyle
Author:
Formation Bio
Formation Bio Appoints Michael Ehlers as Chief Scientific Officer and Head of R&D
July 22, 2026
Formation Bio Doses First Participant in Phase 1 Trial of BLKR201, a CNS-Penetrant TYK2 Inhibitor
June 9, 2026